In the world of investing, spotting stocks that are gaining momentum is a well-worn strategy for those seeking potential profits. These stocks, exhibiting remarkable movements, often sustain their upward trajectory over multiple trading sessions.
Let's take a closer look at four stocks that have shown signs of notable moves this week and might be worth considering for your watchlist
SinglePoint Inc. (OTCQB: SING) has captured the attention of traders over the last few days, even ranking in the top 30 stocks trending on social media. SING opened Tuesday in the mid-$.60 range, hit a high of $1.45 on Wednesday, and now appears to have settled back a bit before potentially making another run. Let’s take a closer look at SING.
SinglePoint Inc. is a multifaceted renewable energy and sustainable lifestyle company that has positioned itself as a prominent player in the pursuit of environmentally friendly, energy-efficient, and health-conscious living solutions. SinglePoint aggressively pursues acquisitions and actively investigates changing growth opportunities in a number of industries, including building safety, energy subscription services, air purification, EV charging infrastructure, and other cutting-edge energy-efficient products that improve well-being and sustainability.
Among SinglePoint's subsidiaries, Boston Solar takes a prominent position as a market leader in the Massachusetts renewable energy landscape. Boston Solar specializes in delivering rooftop solar solutions, EV charging infrastructure, and cutting-edge energy storage options. Their financial performance in FY22 was exceptional, with revenues soaring to an impressive $24.7 million, a substantial increase from the $17.6 million reported in FY2021. The accolade of being consistently recognized as a top Solar Contractor by Solar Power World for eight consecutive years underscores their commitment to delivering top-quality installations and excellent customer service.
Energy Wyze, another subsidiary, plays a pivotal role in the lead generation space for the solar industry. Leveraging a proprietary database of validated, geo-targeted leads and a streamlined automation process for lead generation, Energy Wyze contributes to overall industry efficiency.
In the health and safety sector, BPA Solutions is setting the standards for indoor environment improvement. With thousands of their units deployed in schools nationwide and a commendable revenue of $2.3 million in FY2022, BPA Solutions is committed to enhancing indoor air quality. Furthermore, they've secured a noteworthy $5 million Grant Award Notification from the State of California, indicating their strong foothold in the industry.
In their most recent financial update for Q2 2023, SinglePoint Inc. posted impressive figures. Their record revenue of $8,149,480 during the second quarter reflects a remarkable 79% increase compared to the same period in 2022. They achieved a positive GAAP gross profit, marking a substantial 103% year-over-year increase. Notably, their net loss decreased by approximately 59%, underscoring their commitment to financial growth and stability.
SING is poised to benefit from the Inflation Reduction Act (IRA), which commits $369 billion to support renewable energy projects through enhanced tax credits. The extension of tax credits for direct-ownership solar projects bodes well for the sector's continued growth.
One of the most significant recent developments, announced on Oct. 19, is SinglePoint's acquisition of the remaining 49% of Box Pure Air LLC, now a wholly-owned subsidiary. This move is designed to enhance indoor air quality, particularly in California's schools, where around $800,000 in approved orders are pending shipment. Additionally, in April 2023, the company received approval for various important transactions, including exploring options to sell or spin off Box Pure Air/BPA Solutions, demonstrating their adaptability and positioning within the renewable energy and energy storage sectors.
These recent developments underscore SinglePoint Inc.'s unwavering commitment to sustainability, growth, and its pivotal role in improving indoor air quality in educational institutions across California and beyond.
Mangoceuticals Inc (NASDAQ: MGRX) is making waves in the financial markets, having experienced a significant 18.40% surge in its stock price on October 19th, following the release of their Q3 shareholder update. According to the release, In the third quarter of 2023, MGRX reported impressive financial growth, with sequential revenue increases of 28.8% from Q1 to Q2, followed by an even more substantial 42.5% surge from Q2 to Q3.
One of the primary drivers behind this financial growth is the growing prominence of the Mango brand. With a keen focus on aggressive digital marketing, MGRX has secured sponsorships and promotions with renowned platforms like Barstool Sports and various podcast platforms through Audacy. These partnerships have significantly contributed to the company's success in building a rapidly growing customer base.
A pivotal component of MGRX's strategy is its emphasis on customer acquisition. The company has successfully onboarded a rapidly growing customer base, with an impressive Average Order Value (AOV) of $105. Their goal is to continue increasing their customer base through additional prospecting and retargeting efforts, bolstered by a robust email marketing campaign that has garnered positive results.
Furthermore, MGRX's focus on customer subscriptions and refills has been instrumental in their growth. Subscription sales increased by a substantial 65% from Q1 to Q3, with a sequential growth of 47% from Q2 to Q3, underscoring their accelerating growth curve.
MGRX has also announced exciting initiatives for the fourth quarter, including the development and launch of new men's health and wellness products, a website redesign, an affiliate marketing program, and ongoing marketing efforts.
As MGRX continues to diversify its product offerings, it presents an intriguing opportunity for investors in the men's health and wellness sector.
SeaStar Medical Holding Corporation (NASDAQ: ICU) has been attracting considerable attention in the financial markets, with a notable 37.48% increase in its stock price as of October 19th. This uptick has sparked curiosity among investors looking for potential opportunities.
In recent developments, SeaStar Medical achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting its innovative selective cytochrome device (SCD) a breakthrough device designation. Designed for use in intensive care units (ICU), the SCD aims to assist patients dealing with acute kidney injury (AKI) and acute-on-chronic liver failure. Remarkably, SeaStar Medical has been awarded the third breakthrough device designation by the FDA for the SCD device; this suggests that the device may accelerate the clinical development and regulatory review procedures.
Patients facing advanced liver cirrhosis with acute kidney deterioration due to hyperinflammation are at substantial risk of hepatorenal syndrome-related mortality. SeaStar Medical's SCD offers hope by potentially aiding in kidney recovery, potentially rendering patients eligible for life-saving liver transplants. The prognosis for patients with hepatorenal syndrome is dire if treatment is not received; patients who experience severe acute to chronic liver failure and multiple organ failure within 28 days will all die. In the United States, around 700,000 cases of hepatorenal syndrome are reported annually, with a significant economic burden estimated at $4.2 billion in 2019.
SeaStar Medical's recent stock performance and these groundbreaking developments make it an intriguing player in the penny stock investment landscape.
Assembly Biosciences Inc. (NASDAQ: ASMB) saw a notable 8.91% increase in its stock price on October 19th, as of 2:00 pm, indicating a potential momentum play. This increase could be linked to an important partnership announcement and the company's innovative work in the field of antiviral therapeutics.
Assembly Biosciences is a leading biotechnology company focused on developing innovative small-molecule antiviral therapeutics aimed at transforming the landscape of serious viral diseases and enhancing the lives of patients worldwide. Assembly Bio is committed to improving patient outcomes for those dealing with the severe and enduring consequences of hepatitis B virus (HBV), hepatitis delta virus (HDV), and herpesvirus infections.
An important catalyst for Assembly Bio's recent stock performance is the announcement of its partnership with Gilead Sciences, Inc. (Nasdaq: GILD), a renowned pharmaceutical company. This partnership, spanning 12 years, is geared towards advancing the research and development of novel antiviral therapies. The initial focus will be on Assembly Bio's established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).
As a part of the agreement, Assembly Bio will receive $100 million, comprising an $84.8 million upfront payment and a $15.2 million equity investment from Gilead. The collaboration between GILD and ASMB marks a significant step in addressing unmet medical needs in the field of virology, heralding promising investigational therapies that could lead to substantial advances for patients.
Moreover, Gilead has the option to obtain exclusive rights for each of Assembly Bio's current and future programs, with substantial potential milestones and royalties. Assembly Bio retains the right to co-promote products in the United States for future new programs.
Assembly Biosciences' partnership with Gilead and its groundbreaking antiviral therapeutics have captured the attention of investors. This collaboration opens up new opportunities for advancing virology research and addressing critical unmet medical needs, and it could open up new potential avenues for growth for ASMB.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by SinglePoint Inc. to assist in the production and distribution of content related to SING. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/
